Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01183949
Recruitment Status : Completed
First Posted : August 18, 2010
Last Update Posted : September 23, 2016
Multiple Myeloma Research Consortium
Information provided by (Responsible Party):
Astex Pharmaceuticals

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : December 2014
  Actual Study Completion Date : March 2015
  Certification/Extension First Submitted : September 6, 2016